(King of Prussia, PA; May 14, 2015) - Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, will open a new, state-of-the-art clinical supplies facility in Frankfurt, Germany, in June.
The current good manufacturing practice (cGMP)-compliant facility will triple Theorem’s current clinical supplies capacity, with space for 2,700 square meters of ambient (15 to 25°C) and refrigerated (2 to 8°C) space. The opening also positions Theorem’s clinical supplies hub near the Frankfurt Airport, a major transportation hub.
“We’re excited to have the additional manufacturing and warehousing space and, more importantly, an infrastructure to deliver the flexibility our clients rely on,” said John Potthoff, Theorem president and CEO. “The new facility will enhance speed and scalability while preserving the versatility of our supply solutions.”
Theorem packages, labels, stores, distributes and reclaims pre-randomized study drugs and medical devices for studies worldwide. Theorem also provides qualified person services, as well as a range of temperature-controlled transport and logistics solutions, to facilitate the supply of global clinical trials. The launch of the new facility will strengthen current practices - such as its 24/7/365 storage, continuous monitoring and backup - and provides space for future service expansion.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.